Drug intelligence / Profile preview

CADM1-PEG3-VC-Exatecan

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

CADM1-PEG3-VC-Exatecan: sourced facts only. name: "This study compares the dose-response effectiveness of two CADM1-targeted ADC formulations, CADM1-GGFG-Exatecan and CADM1-PEG3-VC-Exatecan, in preclinical osteosarcoma models." [DOI:10.1158/1538-7445.am2026-7874]; target: "This study compares the dose-response effectiveness of two CADM1-targeted ADC formulations, CADM1-GGFG-Exatecan and CADM1-PEG3-VC-Exatecan, in preclinical osteosarcoma models." [DOI:10.1158/1538-7445.am2026-7874]; developer: "UT MD Anderson Cancer Center, Houston, TX." [DOI:10.1158/1538-7445.am2026-7874]; modality: "Antibody-drug conjugates (ADCs) targeting CADM1 show promise as targeted treatments." [DOI:10.1158/1538-7445.am2026-7874]

Targets

CADM1 (Cell adhesion molecule 1)

Beyond the preview

Go deeper on CADM1-PEG3-VC-Exatecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CADM1-PEG3-VC-Exatecan.